This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
PHAR heads into Q4 results, with Ruconest and Joenja sales in focus, pipeline updates looming, and investors eyeing clarity on key regulatory setbacks.
PHARNegative Net Change CRDLNegative Net Change CRVONegative Net Change ABVXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
BMY Gains 11.4% in a Month: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers rides growth brands like Opdivo and Reblozyl to offset generics, with pipeline catalysts and cost cuts shaping its next phase.
BMYPositive Net Change PFENegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria
by Zacks Equity Research
Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.
REGNPositive Net Change SNYNegative Net Change CSTLNegative Net Change
biotechs
Is Novo Nordisk's GLP-1 Dominance Fading After Lilly's Clinical Wins?
by Ahan Chakraborty
NVO shares plunge 21% after Lilly's Zepbound and oral orforglipron beat its key GLP-1 drugs in head-to-head obesity and diabetes studies, respectively.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot
by Zacks Equity Research
Moderna jumps 4% after EU panel backs mCombriax, its COVID-19-flu combo shot, with phase III data showing stronger immune response vs standalone vaccines.
SNYNegative Net Change GSKPositive Net Change MRNANegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
by Zacks Equity Research
Rocket Pharmaceuticals reports narrower-than-estimated Q4 loss. The company provides key updates on its pipeline candidates. Stock rises in after-hours trading.
ANIPNegative Net Change RCKTNegative Net Change RCUSNegative Net Change CSTLNegative Net Change
biotechs earnings
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
by Zacks Equity Research
Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.
PBYINegative Net Change ANIPNegative Net Change CSTLNegative Net Change
biotechs
PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View
by Zacks Equity Research
Perrigo misses Q4 EPS estimates. Its 2026 sales and profit estimates are below expectations as Infant Formula headwinds persist. Shares slide on weak guidance.
PRGONegative Net Change ANIPNegative Net Change CSTLNegative Net Change
biotechs
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
by Zacks Equity Research
TG Therapeutics misses Q4 earnings estimates, but total revenues surge 78% y/y on strong Briumvi sales. The company reaffirms its 2026 revenue outlook.
TGTXPositive Net Change ANIPNegative Net Change RCUSNegative Net Change CSTLNegative Net Change
biotechs earnings
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
by Zacks Equity Research
NTLA shares jump after fourth-quarter earnings and revenues exceed expectations. The company focuses on lonvo-z and nex-z pipeline programs.
REGNPositive Net Change NTLANegative Net Change RCUSNegative Net Change CSTLNegative Net Change
biotechs earnings